Bevacizumab (glioblastoma use)

Medicare

Part B (clinician-administered)

Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Same drug and coding as bevacizumab; the glioblastoma indication is on label.

Commercial insurance

step therapy common

Preferred biosimilar usually required; some plans apply additional review for recurrent glioblastoma.

Assistance programmes

• Genentech Access Solutions
• Genentech Patient Foundation — Free medicine for eligible patients regardless of insurance type.
• PAN Foundation — Disease-specific co-pay and premium funds; open and closed funds change monthly.
• HealthWell Foundation
• CancerCare Co-Payment Assistance Foundation
• Patient Advocate Foundation Co-Pay Relief

20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.

Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · FDA: Biosimilars. Not medical or financial advice; verify with your plan.

Notes

Not licensed for glioblastoma in the EU or UK (EMA refused 2009); not funded on the NHS except via trials or individual funding requests.

NHS England

Not routinely funded

Sources: NICE search: bevacizumab for glioblastoma. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.